Eptinezumab for the treatment of migraine.

• Scuteri, D. ^[1] ; Corasaniti, M.T. ^[2] ; Tonin, P. ^[3] ; Bagetta, G. ^[1]
  1. [1] University of Calabria

     University of Calabria

     Cosenza, Italia

     
  2. [2] Magna Graecia University

     Magna Graecia University

     Catanzaro, Italia

     
  3. [3] Regional Center for Serious Brain Injuries, S. Anna Institute, Crotone, Italy

  Mostrar afiliaciones +
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 11, 2019 (Ejemplar dedicado a: Noviembre), págs. 695-703
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Eptinezumab (ALD-403) is a genetically engineered humanized IgG1kappa directed towards calcitonin gene-related peptide (CGRP), currently in late-stage clinical development. Eptinezumab targets the pathway of CGRP, importantly implicated in migraine pathophysiology, and may represent the first-to-market infusion therapy for migraine prevention. The background for its approval consists in preclinical data and clinical trials. Here, we provide a comprehensive review of molecular pharmacology, pharmacokinetics, metabolism, efficacy and safety investigated in the preclinical and clinical studies, with insight on possible future directions.